Sandoz A/S Sustainability Profile
Sandoz A/S, a prominent player in the pharmaceutical industry, is headquartered in Denmark (DK) and operates extensively across Europe and beyond. Founded in 1886, Sandoz has established itself as a leader in generic pharmaceuticals and biosimilars, focusing on high-quality, affordable medicines that enhance patient access to essential treatments. The company’s core offerings include a diverse range of generic medications, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. Sandoz is recognised for its commitment to sustainability and patient-centric solutions, positioning itself as a trusted partner in healthcare. With a strong market presence and a history of significant milestones, Sandoz A/S continues to drive advancements in the pharmaceutical sector, making a meaningful impact on global health.
DitchCarbon Score
How does Sandoz A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sandoz A/S's score of 68 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sandoz A/S, headquartered in Denmark (DK), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Sandoz Group AG, which may influence its climate commitments and reporting practices. While Sandoz A/S has not outlined specific reduction targets or achievements, it is important to note that its climate initiatives and commitments may be informed by the broader strategies of Sandoz Group AG. This includes potential targets set under the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded from the parent organisation. As a part of the pharmaceutical industry, Sandoz A/S is likely to align with industry standards for sustainability and climate action, although specific commitments or performance metrics have not been disclosed at this time. The absence of detailed emissions data highlights the need for transparency and accountability in corporate climate strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Sandoz A/S's Industry?
How Carbon Intensive is Sandoz A/S's Location?
Sandoz A/S's Scope 3 Categories Breakdown
Sandoz A/S's Scope 3 emissions, which decreased by 15% last year and decreased by approximately 15% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Sandoz A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sandoz A/S has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
